Cover Image

New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: an EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas

Background - Recently, we performed a meta-analysis based on a literature review for STS trials (published 2003-2018, ≥10 adult patients) to update long-standing reference values for leiomyosarcomas. This work is extended for liposarcomas (LPS) and synovial sarcomas (SS). - Materials and methods - S...

Full description

Saved in:
Bibliographic Details
Main Authors: Kantidakis, Georgios (Author) , Litière, Saskia (Author) , Neven, Anouk (Author) , Vinches, Marie (Author) , Judson, Ian (Author) , Blay, Jean-Yves (Author) , Wardelmann, Eva (Author) , Stacchiotti, Silvia (Author) , D'Ambrosio, Lorenzo (Author) , Marréaud, Sandrine (Author) , van der Graaf, Winette T. A. (Author) , Kasper, Bernd (Author) , Fiocco, Marta (Author) , Gelderblom, Hans (Author)
Format: Article (Journal)
Language:English
Published: 8 September 2022
In: European journal of cancer
Year: 2022, Volume: 174, Pages: 261-276
ISSN:1879-0852
DOI:10.1016/j.ejca.2022.07.010
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2022.07.010
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804922004312
Get full text
Author Notes:Georgios Kantidakis, Saskia Litière, Anouk Neven, Marie Vinches, Ian Judson, Jean-Yves Blay, Eva Wardelmann, Silvia Stacchiotti, Lorenzo D'Ambrosio, Sandrine Marréaud, Winette T. A. van der Graaf, Bernd Kasper, Marta Fiocco, Hans Gelderblom
Description
Summary:Background - Recently, we performed a meta-analysis based on a literature review for STS trials (published 2003-2018, ≥10 adult patients) to update long-standing reference values for leiomyosarcomas. This work is extended for liposarcomas (LPS) and synovial sarcomas (SS). - Materials and methods - Study endpoints were progression-free survival rates (PFSRs) at 3 and 6 months. Trial-specific estimates were pooled per treatment line (first-line or pre-treated) with random effects meta-analyses. The choice of the therapeutic benefit to target in future trials was guided by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). - Results - Information was acquired for 1030 LPS patients (25 trials; 7 first-line, 17 pre-treated, 1 both) and 348 SS patients (13 trials; 3 first-line, 10 pre-treated). For LPS, the overall pooled first-line PFSRs were 69% (95%-CI 60-77%) and 56% (95%-CI 45-67%) at 3 and 6 months, respectively. These rates were 49% (95%-CI 40-57%)/28% (95%-CI 22-34%) for >1 lines. For SS, first-line PFSRs were 74% (95%-CI 58-86%)/56% (95%-CI 31-78%) at 3 and 6 months, and pre-treated rates were 45% (95%-CI 34-57%)/25% (95%-CI 16-36%). Following ESMO-MCBS guidelines, the minimum values to target are 79% and 69% for first-line LPS (82% and 69% for SS) at 3 and 6 months. For pre-treated LPS, recommended PFSRs at 3 and 6 months suggesting drug activity are 63% and 44% (60% and 41% for SS). - Conclusions - New benchmarks are proposed for advanced/metastatic LPS or SS to design future histology-specific phase II trials. More data are needed to provide definitive thresholds for the different LPS subtypes.
Item Description:Online verfügbar: 8 September 2022, Artikelversion: 15 September 2022
Gesehen am 14.08.2023
Physical Description:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2022.07.010

Similar Items